Drägerwerk stock slips as Q3 margin pressure meets stronger orders
Published on 11/10/2026 at 17:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOrders Rise While Margins Tighten
- Currency-adjusted nine-month sales advanced, with both Medical Technology and Safety Technology contributing.
- Third-quarter EBIT declined as higher personnel, logistics and IT costs outweighed stronger order intake.
Drägerwerk enters the final quarter with stronger demand but a weaker quarterly margin. According to AD HOC NEWS, the company reported nine-month results from October 29 that combined higher sales and order intake with renewed pressure on third-quarter profitability.
Drägerwerk stock traded at 99.55 euros on Lang & Schwarz at 17:10 CET on Tuesday, November 10, 2026, 2.21 percent below the Xetra close of Monday, November 9. The current quote is also 2.11 percent below the 101.70-euro level cited in the latest own report at 10:00 CET on the same day.
Sales Growth Meets Cost Pressure
Currency-adjusted sales rose 5.3 percent in the first nine months to 2,453.9 million euros. Medical Technology grew 4.4 percent to 1,367.0 million euros, while Safety Technology advanced 6.5 percent to 1,087.0 million euros.
Group order intake increased 7.0 percent in the third quarter to 926.2 million euros on a currency-adjusted basis. Safety Technology led with a 20.2 percent increase to 451.9 million euros, while Medical Technology order intake declined 3.0 percent to 474.3 million euros.
Profitability Remains The Key Test
Third-quarter sales grew 1.0 percent to 850.8 million euros, but EBIT fell to 48.0 million euros from 56.7 million euros a year earlier. The EBIT margin narrowed to 5.6 percent from 6.8 percent as personnel, logistics and IT costs increased.
Nine-month EBIT rose to 111.8 million euros from 77.1 million euros. The comparison includes 27.9 million euros in customs refunds, including 20.1 million euros attributable to the third quarter, making the durability of the earnings improvement important for investors.
Outlook Holds Ahead Of Capital Markets Day
Drägerwerk kept its 2026 forecast for currency-adjusted sales growth of 2.0 to 6.0 percent and an EBIT margin of 6.0 to 8.0 percent unchanged. Stronger orders support the revenue outlook, while cost control and the conversion of orders into profitable sales remain central for the final quarter.
German equities provide the broader market backdrop for Drägerwerk stock, with the DAX as the relevant domestic benchmark.
Further developments, including the company's Capital Markets Day scheduled for November 18 in Lübeck, can be followed in More news and analyses on Drägerwerk stock.
Drägerwerk AG & Co. KGaA
- Company: Drägerwerk AG & Co. KGaA
- ISIN: DE0005550636
- Ticker: DRW3.DE
- Lang & Schwarz quote: 99.55 euros at 17:10 CET on November 10, 2026
- Change: 2.21 percent below the Xetra close of November 9, 2026
- Xetra close: 101.80 euros on November 9, 2026
- 52-week range: 66.00 to 125.40 euros
- Market capitalization: 1,647,475,137 euros
- Indices: SDAX and TecDAX
